Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research fostered at RDM has increased the accuracy of echocardiogram interpretations, pinpointing many more people at risk of heart disease.

As part of its artificial intelligence showcase, Oxford University interviews Professor Paul Leeson, who heads the Cardiovascular Clinical Research Facility at RDM.

Professor Leeson is one of the founders of Ultromics, which aims to use artificial intelligence to improve the accuracy of echocardiograms interpretation – echocardiograms are the most widely used imaging test for people with heart disease, but it needs an expert to interpret the images and reach a diagnosis.

When the expert is good, then the test can be very accurate. But because levels of experience vary, this can be difficult to control. - Paul Leeson

But Professor Leeson’s team were able to use machine learning to get accurate clinical interpretations which outstripped human doctors, by combining machine learning and clinical know-how to identify associations between features in the echocardiography images and patient outcomes.

Find out more about how this technique could save lives by identifying more people at risk of heart disease.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

High blood sugar levels ‘reprogramme’ stem cells

Findings explain higher risk of heart attack in people with diabetes, even after treatment .

PTH infused insulin pump used as an alternative treatment for young patients with ADH1

Queen Mary University of London and OCDEM researchers develop alternative treatment for patients as young as three months.

Early blood-sugar levels in type 2 diabetes crucial for future prognosis

People who get type 2 diabetes need to gain control of their blood-sugar levels — fast. The years immediately after diagnosis are strikingly critical in terms of their future risk for heart attacks and death.